Literature DB >> 2505612

The epidemiology of mumps in southern Alberta 1980-1982.

W A Falk1, K Buchan, M Dow, J Z Garson, E Hill, M Nosal, M Tarrant, R C Westbury, F M White.   

Abstract

The full spectrum of mumps in Southern Alberta was studied over the years 1980-1982. In the community, a random sample of 3,497 children was tested for prevalence of immunity to mumps. The 1,816 who were not immune were retested after one year. The incidence of new immunity was 16.5%. Most seroconverters had no illness suggestive of mumps. History of previous mumps or immunization were found to be unreliable predictors of serologic immune status. In the family study, information was obtained on 342 cases diagnosed as mumps by family physician recorders. The overall complication rate was 10.8% and the secondary attack rate within families was 11.7%. Hospital records of all 25 patients admitted in Calgary with mumps during the same period were analyzed. Estimated costs of unopposed mumps over 20 years compared with the estimated costs of vaccination showed that a vaccination program could give a benefit-cost ratio between 6.4 and 247. These studies show that mumps is a mild disease with relatively few serious complications or sequelae. Even so, there would be definite medical and economic benefit with immunization. A low-cost addition of mumps vaccine to the immunization program would be justified.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505612     DOI: 10.1093/oxfordjournals.aje.a115395

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  10 in total

1.  Is mumps making a comeback?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-01       Impact factor: 2.471

2.  Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis.

Authors:  Donald R Latner; Marcia McGrew; Nobia Williams; Luis Lowe; Roniel Werman; Eli Warnock; Kathleen Gallagher; Peter Doyle; Sandra Smole; Susan Lett; Noelle Cocoros; Alfred DeMaria; Raimond Konomi; Cedric J Brown; Paul A Rota; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  The Amino Acid at Position 8 of the Proteolytic Cleavage Site of the Mumps Virus Fusion Protein Affects Viral Proteolysis and Fusogenicity.

Authors:  Sarah Hüttl; Markus Hoffmann; Torsten Steinmetzer; Christian Sauder; Nadine Krüger
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

4.  Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.

Authors:  George E Nelson; Annette Aguon; Engracia Valencia; Rita Oliva; Michele Leon Guerrero; Richard Reyes; Anna Lizama; Daryl Diras; Annakutty Mathew; E Jessica Camacho; Moryne-Nicole Monforte; Tai-Ho Chen; Abdirahman Mahamud; Preeta K Kutty; Carole Hickman; William J Bellini; Jane F Seward; Kathleen Gallagher; Amy Parker Fiebelkorn
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

5.  Influenza-Associated Parotitis During the 2014-2015 Influenza Season in the United States.

Authors:  Melissa A Rolfes; Alexander J Millman; Pamela Talley; Lina I Elbadawi; Natalie A Kramer; John R Barnes; Lenee Blanton; Jeffrey P Davis; Stefanie Cole; John J Dreisig; Rebecca Garten; Thomas Haupt; Mary Anne Jackson; Anna Kocharian; Daniel Leifer; Ruth Lynfield; Karen Martin; Lisa McHugh; Sara Robinson; George Turabelidze; Lori A Webber; Meghan Pearce Weinberg; David E Wentworth; Lyn Finelli; Michael A Jhung
Journal:  Clin Infect Dis       Date:  2018-08-01       Impact factor: 9.079

Review 6.  Molecular biology, pathogenesis and pathology of mumps virus.

Authors:  Steven Rubin; Michael Eckhaus; Linda J Rennick; Connor G G Bamford; W Paul Duprex
Journal:  J Pathol       Date:  2015-01       Impact factor: 7.996

7.  Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006.

Authors:  Chee Fu Yung; Nick Andrews; Antoaneta Bukasa; Kevin E Brown; Mary Ramsay
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

Review 8.  Economic evaluations of vaccines in Canada: a scoping review.

Authors:  Ellen R S Rafferty; Heather L Gagnon; Marwa Farag; Cheryl L Waldner
Journal:  Cost Eff Resour Alloc       Date:  2017-05-05

9.  Clinical features of mumps orchitis in vaccinated postpubertal males: a single-center series of 62 patients.

Authors:  Bum Sik Tae; Byeong Kuk Ham; Jae Heon Kim; Jae Young Park; Jae Hyun Bae
Journal:  Korean J Urol       Date:  2012-12-20

10.  Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA.

Authors:  Amy Parker Fiebelkorn; Jacqueline Lawler; Aaron T Curns; Christina Brandeburg; Gregory S Wallace
Journal:  Emerg Infect Dis       Date:  2013       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.